Get the Stockscreener App
7.58
2.02%
0.15
After Hours:
7.72
0.14
+1.85%
Immunitybio Inc stock is traded at $7.58, with a volume of 9.05M.
It is up +2.02% in the last 24 hours and up +3.84% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$7.43
Open:
$7.54
24h Volume:
9.05M
Relative Volume:
0.36
Market Cap:
$7.94B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-19.45
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
+8.91%
1M Performance:
+3.84%
6M Performance:
+252.56%
1Y Performance:
+260.95%
1-Day Range:
$7.43
$7.77
1-Week Range:
$6.73
$7.77
52-Week Range:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.58 | 7.78B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Morningstar
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - PR Newswire
INVESTOR DEADLINE ALERT: ImmunityBio, Inc. (IBRX) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Globe and Mail
ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting - BioSpace
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week - Stocktwits
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
IBRX Deadline Alert: The Gross Law Firm Reminds ImmunityBio, Inc. (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - GlobeNewswire
IBRX Stock Lights Up: Retail Cheers Calls For Trump To ‘Pull The Plug’ On FDA Chief Marty Makary Amid Anktiva Row - Stocktwits
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm - Morningstar
ImmunityBio to Report Q1 Earnings: What's in the Cards? - Yahoo Finance
IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - GlobeNewswire Inc.
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026 Filing Deadline in Securities Class ActionContact Lieff Cabraser - marketscreener.com
IBRX stock climbs overnight: ImmunityBio declares 'all systems go' for Dunkirk Anktiva manufacturing push - MSN
IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Is ImmunityBio, Inc. (IBRX) A Good Stock To Buy Now? - Insider Monkey
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - mydailyrecord.com
IBRX Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages IBRX Investors with Losses to Contact the Firm - PR Newswire
D. Boral Capital Maintains ImmunityBio (IBRX) Buy Recommendation - MSN
symbol__ Stock Quote Price and Forecast - CNN
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
ANKTIVA Strong Demand Propels ImmunityBio, Inc. (IBRX) to Robust Revenue Growth - Insider Monkey
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc.IBRX - Morningstar
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmIBRX - TMX Newsfile
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. - GlobeNewswire
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA - GlobeNewswire
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - GlobeNewswire Inc.
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
IBRX Forecast, Price Target & Analyst Ratings | IMMUNITYBIO INC (NASDAQ:IBRX) - ChartMill
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming DeadlinesIBRX - PR Newswire
ImmunityBio Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein - GlobeNewswire
IBRX Lawsuit Alleges Chairman Allegedly Overstated Drug CapabilitiesImmunityBio Investors Face Losses Following Chairman Allegedly Overstated Drug Capabilities: SueWallSt - PR Newswire
Bladder Cancer Vaccines Market to Reach USD 1,365.83 Million - openPR.com
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
IBRX Lawsuit Alleges Chairman Allegedly Overstated Drug Capabili - GuruFocus
IBRX DEADLINE NOTICE: ImmunityBio, Inc. Investors Encouraged to Contact Kirby McInerney LLP By May 26, 2026 - ACCESS Newswire
ImmunityBio (NASDAQ: IBRX) pairs ANKTIVA surge with 2026 director, auditor votes - Stock Titan
[ARS] ImmunityBio, Inc. SEC Filing - Stock Titan
Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc. - The Joplin Globe
NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc. - The Globe and Mail
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who - GlobeNewswire
ImmunityBio Targets Tough Pancreatic Cancer With New Phase 1 Combo Trial - TipRanks
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential - GlobeNewswire
SHAREHOLDER ALERT Securities Class Action Filed Against ImmunityBio, Inc. (IBRX) - TMX Newsfile
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):